Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
ZNX 0.080 +0.0% TSK 1.05 +0.5% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.330 −4.3% GGA 5.23 −1.3% MDM 0.060 +0.0% WGX 4.30 −2.9% FL 0.410 +0.0% SSRM 35.75 −1.7% CD 0.245 +6.5% GEN 0.065 −7.1% ALS 55.30 −3.8% LIFT 3.35 +6.3% NTR 94.10 −0.2% ICON 0.045 +0.0% ZNX 0.080 +0.0% TSK 1.05 +0.5% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.330 −4.3% GGA 5.23 −1.3% MDM 0.060 +0.0% WGX 4.30 −2.9% FL 0.410 +0.0% SSRM 35.75 −1.7% CD 0.245 +6.5% GEN 0.065 −7.1% ALS 55.30 −3.8% LIFT 3.35 +6.3% NTR 94.10 −0.2% ICON 0.045 +0.0%
Financings

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

By The Northwire Desk — AI Analysis Nov 12, 2025 · 16:02 NRX · 0.71 NurExone Biologic Inc.
NRX · Price

Executive Summary

  • NurExone Biologic Inc. received gross proceeds of over C$3.18 million from the accelerated exercise of its September 2023 and January 2024 warrants.
  • The proceeds will be used for general corporate purposes, working capital, and to support continued development of the exosome‑based therapeutic platform (including ExoPTEN).
  • The company was also announced as a finalist for two prestigious innovation awards (Prix Galien Bridges Awards and Falling Walls Science Breakthroughs), highlighting its scientific visibility.

Key Details

  • Total gross proceeds: C$3,185,994.43.
  • September 2023 Warrants: 2,515,456 warrants exercised at C$0.48 each → C$1,207,418.88.
  • January 2024 Warrants: 5,653,073 warrants exercised at C$0.35 each → C$1,978,575.55.
  • Exercise trigger: Daily average TSXV share price ≥ C$0.83 (Sept‑2023) and ≥ C$0.80 (Jan‑2024) for 20 consecutive trading days.
  • Use of proceeds: General corporate purposes, working capital, and funding ongoing development of the exosome‑based therapeutic platform.
  • Management comments: CEO Dr. Lior Shaltiel emphasized full participation by warrant holders and strengthened financial position; CFO Eran Ovadya highlighted investor confidence and enhanced ability to allocate resources toward clinical development.
  • Award nominations: Finalist for the Galien Foundation’s inaugural Prix Galien Bridges Awards (Stockholm, Dec 5 2025) and finalist in the Falling Walls Science Breakthroughs of the Year Summit (Berlin).

Notable Quotes

“We are very pleased with the full participation from warrantholders during the accelerated exercise period… This additional capital enhances our financial strengths as we continue advancing ExoPTEN and our therapeutic pipeline towards clinical readiness.” – Dr. Lior Shaltiel, CEO

“The full participation of these warrantholders reflects investor confidence in NurExone’s strategy… The resulting funds provide further financial stability, enabling us to efficiently allocate resources towards clinical development and key operational priorities.” – Eran Ovadya, CFO

Read the original news release →

More from NurExone Biologic Inc.

Jun 30, 2026 · 08:31

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

Financings Jun 24, 2026 · 17:01

Early-stage exosome developer secures Mexican distribution MOU while navigating a tight cash runway and going concern warning.

M&A / Property Jun 01, 2026 · 08:02

NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

Earnings May 19, 2026 · 16:04

NurExone Expands IP Portfolio with South Korea Patent Grant Amidst Manufacturing Push

Other May 14, 2026 · 16:05

NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

Other Apr 27, 2026 · 16:03

Patent Portfolio Expansion Masks Underlying Liquidity Constraints in Exosome Developer

M&A / Property